



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Chu et al.

Serial No.: 10/665,936

Confirmation No.: Unknown

Filed:

September 19, 2003

For:

 $\omega$ 

Group Art Unit: Unknown

Examiner:

Unknown

**Customer Number:** 

28390

**DELIVERY OF** 

THERAPEUTICS TO TREAT

**ANEURYSMS** 

CERTIFICATE OF MAILING

37 CFR 1.8

I hereby certify that this correspondence is being deposited on December 15, 2003 with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA-22313-1450.

**Esther Marques** 

Alexandria, VA 22313-1450

Commissioner for Patents

Dear Sir or Madame:

MAIL STOP DD

P.O. Box 1450

## INFORMATION DISCLOSURE STATEMENT

The Applicants, and the Attorney who signs below on the basis of the information supplied by the inventor and the information in his file, submit herewith patents, publications, or other information of which they are aware, which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56.

While the information submitted in this Information Disclosure Statement may be material pursuant to 37 CFR § 1.56, it is not intended to constitute an admission that any patent, publication, or other information referred to therein is prior art for this invention unless specifically designated as such.

In accordance with 37 CFR § 1.97, this Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other possibly material information as defined under 37 CFR § 1.56(a) exists.

The patents and/or publications submitted herewith are set forth on the attached Forms PTO-SB08A and SB08B.

While we believe that no fee is due, if the sum of \$180.00 is due under 37 CFR § 1.17(p) pursuant to § 1.97, the Commissioner is hereby authorized to charge

241737\_1

this fee, and any other fee necessary to make this submission timely, to the Deposit Account No. 20-0782/P1768 (MEDT/0024/SB).

Respectfully submitted,

Sarah J. Brashears

Registration No. 38,087 Telephone: (650) 330-2310 Facsimile: (650) 330-2314 Attorney for Applicant(s)

2

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

August 18, 2003

Complete if Known

10/665,936

Chu et al.

Unknown

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number

First Named Inventor

Filing Date

Art Unit

OIL

DEC 1 7 2003

Sheet | 1

## Under the Paperwoin ADENABED Stitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Examiner Name** Unknown P1768 (MEDT/0024) Attorney Docket Number - 3 of

			U. S. PATEN	T DOCUMENTS	_
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
	1	Number-Kind Code <sup>2 (# known)</sup>	05/30/2002	Markenetal	go. oopp oo.
		<sup>US-</sup> 2002/0065546		Machan et al.	
	2	<sup>US-</sup> 5,538,504	07/23/1996	SciMed Life Systems, Inc.	
	3_	<sup>US-</sup> 5,670,161	09/23/1997	Healy et al.	
	4	<sup>US-</sup> 5,834,449	12/10/1998	The Research Foundation of State	University of
		US-		New York; Washington University	
	5	<sup>US-</sup> 6,159,239	12/12/2000	Prodesco, Inc.	
	6	<sup>US-</sup> 6,190,353	02/20/2001	TransVascular, Inc.	
	7	<sup>US-</sup> 6,302,870	10/16/2001	Precision Vascular Systems, Inc.	
	8	<sup>US-</sup> 6,344,035	02/05/2002	Surmodics, Inc.	
	9	<sup>US-</sup> 6,348,050	02/19/2002	Medtronic, Inc.	
	10	<sup>US-</sup> 6,364,903	04/02/2002	Meadox Medicals, Inc.	
	11	<sup>US-</sup> 6,368,346	04/09/2002	American Medical Systems, Inc.	
	12	<sup>US-</sup> 6,371,970	04/16/2002	Incept LLC	
	13	<sup>US-</sup> 6,376,742	04/23/2002	Zdrahala et al.	
	14	<sup>US-</sup> 6,387,121	05/14/2002	Inflow Dynamics Inc.	100
	15	<sup>US-</sup> 6,451,373	09/17/2002	Advanced Cardiovascular Systems	, Inc.
	16	<sup>US-</sup> 6,506,410	01/14/2003	Kong Kook Pharmaceutical Co., Lt	d.
	17	<sup>US-</sup> 6,514,515	02/04/2003	Tepha, Inc.	
	18	<sup>US-</sup> 6,531,154	03/11/2003	Brown University Research Found	ation

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T
	1	WO-02/15824-A2	02/28/2002	Kensey Nash Corporation		
						L
						L
						L
			1			ı

Examiner Date	
Signature Considered	
_ `	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND** TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC Undertifie Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	te for form 1449/PTO				Complete if Known
0				Application Number	10/665,936
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	September 19, 2003
				First Named Inventor	Chu et al.
	(Use as many she	ate se n	acaesand	Art Unit	Unknown
	(USE as many site	eis as ii	ecessary)	Examiner Name	Unknown
Sheet	2	of	3	Attorney Docket Number	P1768 (MEDT/0024)

NON PATENT LITERATURE DOCUMENTS	 		
Initials* No. the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  "Beta-Blockers (Beta-Adrenergic Blocking Drugs)." Texas Heart Institute Heart Information Center. 18 March 2003 <a href="http://www.tmc.edu/thi/betameds.html">http://www.tmc.edu/thi/betameds.html</a> "Beta Blockers." Cardiac Consultants, 18 March 2003 <a href="http://www.cardiacconsultants.com/beta.htm">http://www.cardiacconsultants.com/beta.htm</a> "Beta Blockers (Beta-Adrenergic Bockers, Beta 1 Blockers, Beta 2 Blockers, B-Blockers)."  HeartCenterOnline, 18 March 2003 <a href="http://www.bardicenteronline.com/myheartdr/common/articles.cfm?ARTID=331">http://www.bardicenteronline.com/myheartdr/common/articles.cfm?ARTID=331</a> .   "beta-blocker." Bartleby.com. 18 March 2003 <a href="http://www.bartleby.com/65/be/beta-b.html">http://www.bartleby.com/65/be/beta-b.html</a> .  Slaiby, Jeffrey M. et al. "Expansion of aortic aneurysms is reduced by proparanolol in a hypertensive rat model." Journal of Vascular Surgery. 21 January 2002 <a href="http://www.harcourthealth.com/scripts/om.dli/serve?action=searchDB&amp;searchDBfor=art&amp;a">http://www.harcourthealth.com/scripts/om.dli/serve?action=searchDB&amp;searchDBfor=art&amp;a</a> .  Vine, N. et al. "Metalloproteinases in degenerative aortic disease." Clinical Science 1991, 81: 233-239.  Goodman, Louis Sanford and Albert Gilman. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2001.  Jackson, Edwin K. "Renin and Angiotensin." 809-835.  Liao, Shixiong et al. "Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors." Journal of Vascular Surgery. May 2001, 33, No. 5: 1057-1064.  Chaikof, Elliot L. et al. "Biomaterials and Scaffolds in Reparative Medicine." Annals New York	 	NON PATENT LITERATURE DOCUMENTS	
1 18 March 2003 <a href="http://www.tmc.edu/thi/betameds.html">http://www.tmc.edu/thi/betameds.html</a> .  2 "Beta Blockers." Cardiac Consultants. 18 March 2003 <a href="http://www.cardiacconsultants.com/beta.htm">http://www.cardiacconsultants.com/beta.htm</a> .  3 HeartCenterOnline. 18 March 2003 <a href="http://www.beartcenteronline.com/myheartdr/common/articles.cfm?ARTID=331">http://www.beartcenteronline.com/myheartdr/common/articles.cfm?ARTID=331</a> .  4 "beta-blocker." Bartleby.com. 18 March 2003 <a href="http://www.bartleby.com/65/be/beta-b.html">http://www.bartleby.com/65/be/beta-b.html</a> .  5 Slaiby, Jeffrey M. et al. "Expansion of aortic aneurysms is reduced by proparanolol in a hypertensive rat model." Journal of Vascular Surgery. 21 January 2002 <a href="http://www.harcourthealth.com/scripts/om.dli/serve?action=searchDB&amp;searchDBfor=art&amp;a">http://www.harcourthealth.com/scripts/om.dli/serve?action=searchDB&amp;searchDBfor=art&amp;a</a> .  6 Vine, N. et al. "Metalloproteinases in degenerative aortic disease." Clinical Science 1991, 81: 233-239.  7 Goodman, Louis Sanford and Albert Gilman. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2001.  8 Jackson, Edwin K. "Renin and Angiotensin." 809-835.  9 Liao, Shixiong et al. "Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors." Journal of Vascular Surgery. May 2001, 33, No. 5: 1057-1064.  Chaikof, Elliot L. et al. "Biomaterials and Scaffolds in Reparative Medicine." Annals New York	Cite No. <sup>1</sup>	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	T <sup>2</sup>
Seta Blockers (Beta-Adrenergic Bockers, Beta 1 Blockers, Beta 2 Blockers, B-Blockers)."	1	"Beta-Blockers (Beta-Adrenergic Blocking Drugs)." <u>Texas Heart Institute Heart Information Center.</u> 18 March 2003 <a href="http://www.tmc.edu/thi/betameds.html">http://www.tmc.edu/thi/betameds.html</a> .	
HeartCenterOnline, 18 March 2003   Shittp://www.heartcenteronline.com/myheartdr/common/articles.cfm?ARTID=331>.     "beta-blocker." Bartleby.com. 18 March 2003   Shittp://www.bartleby.com/65/be/beta-b.html>.     5   Slaiby, Jeffrey M. et al. "Expansion of aortic aneurysms is reduced by proparanolol in a hypertensive rat model." Journal of Vascular Surgery. 21 January 2002   Shittp://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&searchDBfor=art&a>.     6   Vine, N. et al. "Metalloproteinases in degenerative aortic disease." Clinical Science 1991, 81: 233-239.     7   Goodman, Louis Sanford and Albert Gilman. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2001.     8   Jackson, Edwin K. "Renin and Angiotensin." 809-835.     9   Liao, Shixiong et al. "Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors." Journal of Vascular Surgery. May 2001, 33, No. 5: 1057-1064.     Chaikof, Elliot L. et al. "Biomaterials and Scaffolds in Reparative Medicine." Annals New York	2		
Slaiby, Jeffrey M. et al. "Expansion of aortic aneurysms is reduced by proparanolol in a hypertensive rat model." Journal of Vascular Surgery. 21 January 2002 <a href="http://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&amp;searchDBfor=art&amp;a&gt;.">http://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&amp;searchDBfor=art&amp;a&gt;.</a> Vine, N. et al. "Metalloproteinases in degenerative aortic disease." Clinical Science 1991, 81: 233-239.  Goodman, Louis Sanford and Albert Gilman. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2001.  Jackson, Edwin K. "Renin and Angiotensin." 809-835.  Liao, Shixiong et al. "Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors." Journal of Vascular Surgery. May 2001, 33, No. 5: 1057-1064.  Chaikof, Elliot L. et al. "Biomaterials and Scaffolds in Reparative Medicine." Annals New York	3	HeartCenterOnline, 18 March 2003	
hypertensive rat model." Journal of Vascular Surgery. 21 January 2002 <a href="http://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&amp;searchDBfor=art&amp;a&gt;.">http://www.harcourthealth.com/scripts/om.dll/serve?action=searchDB&amp;searchDBfor=art&amp;a&gt;.</a> Vine, N. et al. "Metalloproteinases in degenerative aortic disease." Clinical Science 1991, 81: 233-239.  Goodman, Louis Sanford and Albert Gilman. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2001.  Jackson, Edwin K. "Renin and Angiotensin." 809-835.  Liao, Shixiong et al. "Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors." Journal of Vascular Surgery. May 2001, 33, No. 5: 1057-1064.  Chaikof, Elliot L. et al. "Biomaterials and Scaffolds in Reparative Medicine." Annals New York	4	"beta-blocker." <u>Bartleby.com.</u> 18 March 2003 <a href="http://www.bartleby.com/65/be/beta-b.html">http://www.bartleby.com/65/be/beta-b.html</a> .	
Goodman, Louis Sanford and Albert Gilman. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2001.  Jackson, Edwin K. "Renin and Angiotensin." 809-835.  Liao, Shixiong et al. "Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors." Journal of Vascular Surgery. May 2001, 33, No. 5: 1057-1064.  Chaikof, Elliot L. et al. "Biomaterials and Scaffolds in Reparative Medicine." Annals New York	5	hypertensive rat model." Journal of Vascular Surgery. 21 January 2002	
7 York: McGraw-Hill, 2001.  Jackson, Edwin K. "Renin and Angiotensin." 809-835.  Liao, Shixiong et al. "Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors." Journal of Vascular Surgery. May 2001, 33, No. 5: 1057-1064.  Chaikof, Elliot L. et al. "Biomaterials and Scaffolds in Reparative Medicine." Annals New York	6	Vine, N. et al. "Metalloproteinases in degenerative aortic disease." <u>Clinical Science</u> 1991, 81: 233-239.	
Liao, Shixiong et al. "Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors." Journal of Vascular Surgery. May 2001, 33, No. 5: 1057-1064.  Chaikof, Elliot L. et al. "Biomaterials and Scaffolds in Reparative Medicine." Annals New York	 7	Goodman, Louis Sanford and Albert Gilman. The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2001.	
treatment with angiotensin-converting enzyme inhibitors." <u>Journal of Vascular Surgery</u> . May 2001, 33, No. 5: 1057-1064.  Chaikof, Elliot L. et al. "Biomaterials and Scaffolds in Reparative Medicine." <u>Annals New York</u>	8	Jackson, Edwin K. "Renin and Angiotensin." 809-835.	
	 9	treatment with angiotensin-converting enzyme inhibitors." Journal of Vascular Surgery. May 2001,	
	10		

Examiner Date Signature Considered			
	Examiner	Date	
	Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions described by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions give the process. Any comments on the amount of time you require to complete this form and/or suggestions give the process of the chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Do Not SeND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te forsorm 1449/PTO	uction A	or or 1995, no persons ar	required to respond to a collection of information unless it contains a valid OMB control number Complete if Known				
SADEM				Application Number	10/665,936	_		
INF	ORMATION	DIS	CLOSURE	Filing Date	September 19, 2003	_		
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Chu et al.			
	(lico as many cho	ote se n	ococcand	Art Unit	Unknown			
(Use as many sheets as necessary)				Examiner Name	Unknown			
Sheet	3	of	3	Attorney Docket Number	PA1768 (MEDT/0024)			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	11	Griffith, Linda G. "Emerging Design Principles in Biomaterials and Scaffolds or Tissue Engineering." Annals New York Academy of Sciences 2002, 961: 83-95.	
	12	Ochoa, Erin R. et al. "An Overview of the Pathology and Approaches to Tissue Engineering."  Annals New York Academy of Sciences 2002, 979: 10-26.	
	!		

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.